Lab
OIG excluded
Labtech Diagnostic, LLC
Labtech Diagnostic, LLC was paid $10.73M by Medicaid between Jan 2018 and Dec 2021, across 162 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 28% of everything it billed.
33Billing provider infoLABTECH DIAGNOSTIC, LLC
ANDERSON, SC 29621
ANDERSON, SC 29621
33aNPI1386915700assigned 01/17/2012
33bProvider typeClinical Medical Laboratory
28Total paid$10.73M
24GClaims496,266
24DCodes billed162
24AFirst – last monthJan 2018 – Dec 2021
Compared with peers
Next to other Clinical Medical Laboratory providers in South Carolina
Rank by total paid#3 of 39
Median peer was paid$403K
This provider vs. median27×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
OIG exclusionListed on the federal exclusion list (12/19/2025).
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 88,748 | $1.92M | |
| 2019 | 98,385 | $1.98M | |
| 2020 | 146,808 | $3.57M | |
| 2021 | 162,325 | $3.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 28% | 18,948 | 10,235 | $3.00M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 16% | 22,747 | 13,560 | $1.72M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 8.7% | 14,297 | 11,547 | $933K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.8% | 15,625 | 14,487 | $410K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.2% | 22,829 | 21,268 | $341K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.8% | 1,203 | 1,043 | $302K |
| 80053 | Comprehensive metabolic panel | 2.2% | 26,907 | 24,938 | $233K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 31,614 | 29,345 | $224K |
| 80061 | Lipid panel | 1.8% | 17,767 | 16,407 | $190K |
| 86235 | 1.5% | 2,403 | 1,263 | $160K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.4% | 8,322 | 5,193 | $148K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.3% | 5,210 | 4,626 | $135K |
150 more codes
| 80074 | 1.2% | 2,938 | $126K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.2% | 5,180 | $124K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.0% | 12,932 | $109K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,615 | $79K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,572 | $71K |
| 82607 | <1% | 5,505 | $70K | |
| 87390 | <1% | 3,891 | $68K | |
| 80332 | <1% | 2,481 | $62K | |
| 80335 | <1% | 2,481 | $57K | |
| 80339 | <1% | 2,108 | $57K | |
| 86769 | <1% | 1,464 | $55K | |
| 86003 | <1% | 1,097 | $51K | |
| 84315 | <1% | 34,057 | $47K | |
| 82746 | <1% | 3,831 | $47K | |
| 84403 | <1% | 2,360 | $46K | |
| 86702 | <1% | 3,888 | $46K | |
| 84439 | <1% | 5,993 | $45K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 523 | $45K |
| 80338 | <1% | 2,481 | $44K | |
| 80355 | <1% | 2,480 | $42K | |
| 80366 | <1% | 2,480 | $42K | |
| 83970 | <1% | 1,515 | $40K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 685 | $39K |
| 82570 | <1% | 25,768 | $37K | |
| 87581 | <1% | 1,338 | $37K | |
| 87486 | <1% | 1,329 | $37K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,465 | $37K |
| 82728 | <1% | 3,183 | $34K | |
| 86696 | <1% | 1,812 | $34K | |
| 87088 | <1% | 4,370 | $34K | |
| 86701 | <1% | 3,890 | $33K | |
| 86038 | <1% | 3,011 | $33K | |
| 84466 | <1% | 3,212 | $32K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,104 | $31K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 704 | $31K |
| 80368 | <1% | 1,471 | $30K | |
| 83704 | <1% | 1,713 | $30K | |
| 84153 | <1% | 1,742 | $29K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,287 | $29K |
| 86780 | <1% | 2,165 | $29K | |
| 82172 | <1% | 1,130 | $28K | |
| 84480 | <1% | 2,637 | $28K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,169 | $27K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,485 | $27K |
| 82670 | <1% | 1,606 | $25K | |
| 80367 | <1% | 1,471 | $25K | |
| 86376 | <1% | 2,333 | $24K | |
| 84270 | <1% | 1,695 | $24K | |
| 84481 | <1% | 1,562 | $24K | |
| 82239 | <1% | 1,837 | $23K | |
| 86695 | <1% | 1,797 | $23K | |
| 80373 | <1% | 1,471 | $23K | |
| 80372 | <1% | 1,471 | $23K | |
| 80342 | <1% | 2,479 | $23K | |
| 86200 | <1% | 1,818 | $22K | |
| 80365 | <1% | 770 | $22K | |
| 83540 | <1% | 4,102 | $22K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 796 | $21K |
| 83986 | <1% | 24,201 | $21K | |
| 83001 | <1% | 1,522 | $21K | |
| 83735 | <1% | 3,771 | $20K | |
| 83880 | <1% | 1,071 | $19K | |
| 86225 | <1% | 1,508 | $19K | |
| 80076 | <1% | 2,963 | $18K | |
| 86803 | <1% | 1,346 | $18K | |
| 86160 | <1% | 1,076 | $17K | |
| 86140 | <1% | 3,191 | $16K | |
| 83002 | <1% | 1,384 | $16K | |
| 87077 | <1% | 2,056 | $16K | |
| 84144 | <1% | 1,288 | $15K | |
| 83516 | <1% | 1,300 | $14K | |
| 87186 | <1% | 1,723 | $14K | |
| 85652 | <1% | 5,539 | $13K | |
| 83695 | <1% | 1,208 | $13K | |
| 80360 | <1% | 770 | $13K | |
| 83992 | <1% | 770 | $12K | |
| 82627 | <1% | 1,095 | $12K | |
| 84146 | <1% | 700 | $12K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,184 | $12K |
| 86431 | <1% | 2,087 | $11K | |
| 83655 | <1% | 1,018 | $11K | |
| 84702 | <1% | 1,117 | $11K | |
| 84550 | <1% | 2,771 | $10K | |
| 86318 | <1% | 901 | $10K | |
| 86147 | <1% | 192 | $9K | |
| 80369 | <1% | 439 | $9K | |
| 84305 | <1% | 769 | $8K | |
| 82785 | <1% | 515 | $7K | |
| 86039 | <1% | 673 | $7K | |
| 82533 | <1% | 794 | $7K | |
| 83721 | <1% | 1,112 | $7K | |
| 86141 | <1% | 654 | $6K | |
| 84402 | <1% | 256 | $6K | |
| 82550 | <1% | 941 | $5K | |
| 81001 | <1% | 1,947 | $5K | |
| 83525 | <1% | 893 | $5K | |
| 87070 | <1% | 534 | $5K | |
| 84484 | <1% | 463 | $4K | |
| 84681 | <1% | 643 | $4K | |
| 82043 | <1% | 899 | $4K | |
| 84436 | <1% | 626 | $4K | |
| 87799 | <1% | 44 | $4K | |
| 84100 | <1% | 1,256 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 53 | $4K |
| 87634 | <1% | 51 | $3K | |
| 82610 | <1% | 568 | $3K | |
| 80050 | General health panel | <1% | 340 | $2K |
| 81025 | <1% | 351 | $2K | |
| 87299 | <1% | 75 | $2K | |
| 87481 | <1% | 80 | $2K | |
| 85610 | <1% | 524 | $2K | |
| 84156 | <1% | 630 | $2K | |
| 83003 | <1% | 499 | $2K | |
| 82977 | <1% | 644 | $2K | |
| 87511 | <1% | 68 | $2K | |
| 82085 | <1% | 556 | $2K | |
| 85027 | <1% | 295 | $2K | |
| 83090 | <1% | 261 | $1K | |
| 86677 | <1% | 72 | $1K | |
| 83690 | <1% | 168 | $998.01 | |
| 85018 | <1% | 406 | $869.64 | |
| 82248 | <1% | 212 | $835.12 | |
| 81002 | <1% | 338 | $751.57 | |
| 87075 | <1% | 91 | $711.43 | |
| 85730 | <1% | 141 | $690.95 | |
| 85045 | <1% | 181 | $688.74 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 13 | $610.19 |
| 82784 | <1% | 29 | $609.47 | |
| 87340 | <1% | 53 | $463.03 | |
| 85379 | <1% | 52 | $453.93 | |
| 86480 | <1% | 16 | $442.52 | |
| 87512 | <1% | 14 | $433.21 | |
| 82150 | <1% | 77 | $396.79 | |
| 86317 | <1% | 16 | $394.04 | |
| 87808 | <1% | 33 | $388.30 | |
| 80164 | <1% | 45 | $375.66 | |
| 87205 | <1% | 92 | $332.08 | |
| 83550 | <1% | 63 | $306.34 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 279 | $243.55 |
| 80069 | <1% | 13 | $99.65 | |
| 87625 | <1% | 14 | $63.26 | |
| 82040 | <1% | 14 | $50.85 | |
| 86900 | <1% | 13 | $38.42 | |
| 86901 | <1% | 13 | $38.42 | |
| 83722 | <1% | 300 | $5.69 | |
| 83698 | 0% | 151 | $0.00 | |
| 82947 | 0% | 127 | $0.00 | |
| 83876 | 0% | 126 | $0.00 | |
| 83520 | 0% | 140 | $0.00 | |
| 84378 | 0% | 137 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLABASHABAZID, ALYOSEF (PRESIDENT/OWNER)